DSIP
Stocked in 5mg, 10mg, 15mg at MontanaPep in Great Falls, Montana. Sold for laboratory research use only.
| Size | Catalog no. | Price per vial |
|---|---|---|
| 5mg | DS5 | $20 |
| 10mg | DS10 | $35 |
| 15mg | DS15 | $45 |
Classification
Nonapeptide named for an effect that was never mechanistically confirmed
Structure and chemistry
DSIP, delta sleep-inducing peptide, is the nonapeptide Trp-Ala-Gly-Gly-Asp-Ala-Ser-Gly-Glu, molecular weight approximately 849 daltons. It is amphiphilic and its sequence resembles no other known peptide family. One chemical detail from the original characterization has direct practical consequences: only the pure alpha-aspartyl form is highly active, while the beta-aspartyl isomer is not — same atoms, different linkage, different activity.
What the published research shows
DSIP has an estimated 1,500 published references accumulated over nearly five decades, and yet its central claim remains unresolved. As a 2006 review in the Journal of Neurochemistry put it directly, the link between DSIP and sleep has never been further characterized, and the hypothesis of DSIP as a sleep factor is poorly documented and weak. Reported clinical use in European and Russian settings for insomnia, pain and substance withdrawal exists, but studies are small and results inconsistent.
Mechanism of action
Not established. This is the crux of the DSIP problem: after nearly fifty years, no DSIP gene, no precursor protein, and no receptor has ever been identified. Reported activities include modulation of GABAergic, glutamatergic and opioidergic signalling, anticonvulsant effects in animal seizure models, and blood-brain barrier penetration — but without a known receptor these remain observations rather than a mechanism.
Development history
DSIP was not designed. In 1977 the Schoenenberger-Monnier group in Basel isolated it from the cerebral venous blood of rabbits that had been placed into a sleep-like state by low-frequency electrical stimulation of the intralaminar thalamic nuclei. The idea was that a sleeping brain might release a substance that causes sleep, and that such a substance could be captured from the blood leaving it.
Current regulatory status
DSIP is not approved by the FDA or any Western regulator for any indication. Emideltide (DSIP) was nominated to FDA’s bulk drug substances list for pharmacy compounding; the nomination was withdrawn. The compound is named for a proposed function that five decades of research has not confirmed.
Analytical testing
The alpha-aspartyl versus beta-aspartyl issue makes DSIP a genuinely demanding analytical target. Aspartic acid residues can isomerize during synthesis and storage, and the original characterization established that only the alpha form is highly active. Ordinary reverse-phase HPLC may not separate these isomers well, so a meaningful COA needs an identity method able to address isomeric purity, not just a purity percentage and a mass.
Ordering from Great Falls
MontanaPep, also known as Montana Peptides, is an independently owned supplier based at 715 13th Ave S, Great Falls, Montana. Local pickup is available by arrangement, and we ship to research addresses across Montana including Billings, Missoula, Bozeman, Helena, Butte, Kalispell and Havre. Call (406) 799-0812 or email customerservice@montanapep.com.